paliperidone 6 mg
1 INDICATIONS AND USAGE Paliperidone is an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1.1 ) • Adults: Efficacy was established in three 6-week trials and one maintenance trial. ( 14.1 ) • Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. ( 14.1 ) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. ( 1.2 ) • Efficacy was established in two 6-week trials in adult patients. ( 14.2 ) 1.1 Schizophrenia Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies (14.1 )] . The efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. 1.2 Schizoaffective Disorder Paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see Clinical Studies (14.2 )] . The efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults.
sun pharmaceutical industries, inc.
ROUND YELLOW 766
Related Pills
paliperidone 3 mg
sun pharmaceutical industries, inc.
erlotinib 100 MG Oral Tablet
teva pharmaceuticals usa, inc.
erlotinib 150 MG Oral Tablet
teva pharmaceuticals usa, inc.
everolimus tablet
teva pharmaceuticals usa, inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING
PALIPERIDONE extended-release tablets are available in the following strengths and packages. 1.5 mg tablets are brown, circular, biconvex, beveled edged, film-coated tablets imprinted with “744” in black ink on one side and plain on the other side. NDC Number Size 47335-744-83 Bottle of 30 Tablets with Child Resistant Cap 47335-744-88 Bottle of 100 Tablets with Child Resistant Cap 3 mg tablets are white to off-white, circular, biconvex, beveled edged, film-coated tablets imprinted with “765” in black ink on one side and plain on the other side. NDC Number Size 47335-765-83 Bottle of 30 Tablets with Child Resistant Cap 47335-765-88 Bottle of 100 Tablets with Child Resistant Cap 6 mg tablets are yellow, circular, biconvex, beveled edged, film-coated tablets imprinted with “766” in black ink on one side and plain on the other side. NDC Number Size 47335-766-83 Bottle of 30 Tablets with Child Resistant Cap 47335-766-88 Bottle of 100 Tablets with Child Resistant Cap 9 mg tablets are pink, circular, biconvex, beveled edged, film-coated tablets imprinted with “767” in black ink on one side and plain on the other side. NDC Number Size 47335-767-83 Bottle of 30 Tablets with Child Resistant Cap 47335-767-88 Bottle of 100 Tablets with Child Resistant Cap Storage and Handling Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Protect from moisture. Keep out of reach of children.
More pills like ROUND 766